Buy Torrent Pharmaceuticals; target of Rs 5581: Geojit Financial Services

Moneycontrol • 1 day ago

Original source

Key Investment Pillars

  • The integration of J.B. Chemicals and Pharmaceuticals Limited is progressing smoothly, with targeted benefits of Rs. 450cr in cost synergies now expected within two years versus three earlier, supporting profitability.
  • Torrent expects sustained momentum from its chronic therapy portfolio, supported by continued expansion of the Curatio business, increasing contribution from the semaglutide portfolio, and deeper penetration across key therapeutic segments.
  • International operations are gradually recovering from integration-related disruptions, with strength in Brazil and the US, along with ongoing synergy benefits, expected to support growth visibility and reinforce long-term earnings prospects.
  • Management plans to maintain the combined India field force at ~9,100 through FY27, with a potential expansion to 9,500-9,600 in FY28 based on growth requirements.

Thesis Validation Checklist

  • Investors should watch for signs of sustained momentum in the chronic therapy portfolio, successful integration of J.B. Chemicals and Pharmaceuticals Limited, and continued expansion of the Curatio business and semaglutide portfolio.
  • Key signals to monitor include revenue growth, EBITDA margin expansion, and progress in achieving cost synergies from the integration.
  • A recovery in market share for injectable semaglutide following supply normalization and the realization of revenue synergies from cross-selling initiatives and broader distribution of J.B. Chemicals and Pharmaceuticals Limited brands across the combined franchise will be important to validate the thesis.